Pfizer (Japan)

Recent papers from Pfizer (Japan)

1. Landscape and Time Course of Comprehensive Genomic Profiling Use in Japanese Patients With Cancer: A Retrospective StudyCancer Science · 2026
2. Learning from Case Studies: Recent Trends and Challenges in the Design of Pragmatic Clinical TrialsJapanese Journal of Biometrics · 2026
3. Caregiver Experiences with Daily and Weekly Growth Hormone Injections in Japanese Children: A Cross-sectional SurveyDrugs - Real World Outcomes · 2026
4. Cost-effectiveness analysis of elranatamab versus physician’s choice of treatment (non–BCMA-directed regimens) in patients with triple class exposed multiple myeloma in JapanJournal of Medical Economics · 2026
5. Comparative Cost-Effectiveness of Advanced Treatment Sequences for Moderately to Severely Active Ulcerative Colitis in JapanAdvances in Therapy · 2026
6. Clinical Pharmacokinetics and Pharmacodynamics of Marstacimab, an Anti-tissue Factor Pathway Inhibitor Monoclonal Antibody, in Adolescent and Adult Participants with HemophiliaClinical Pharmacokinetics · 2026
7. Real-World Testing Landscape and Costs of Companion Diagnostics and Comprehensive Genomic Profiling Across Nine Solid Tumors in Japan: A 10-Year AnalysisOncology and Therapy · 2026
8. Physiologically Based Pharmacokinetic Modeling to Assess Transporter‐Mediated Drug–Drug Interactions in Support of Labeling Recommendations for Zavegepant Nasal SprayClinical Pharmacology & Therapeutics · 2026
9. Pharmacological properties and clinical efficacy of sphingosine 1-phosphate (S1P) receptor modulator, Etrasimod (Velsipity® 2 mg tablets)Folia Pharmacologica Japonica · 2026
10. Dose Selection for Ceftibuten Combined with Avibactam Tomilopil, a Potential Oral Alternative to Carbapenems for Patients with Complicated Urinary Tract InfectionsThe Journal of Clinical Pharmacology · 2026
11. Comparative Safety Analysis of Targeted Synthetic and Biologic Disease‐Modifying Antirheumatic Drugs Among Patients With Rheumatoid Arthritis: A Nationwide Cohort Study in JapanInternational Journal of Rheumatic Diseases · 2026
12. Multimorbidity Among Patients Receiving Home Care in Japan: Prevalence, Levels, and Association With Emergency Home VisitsJournal of General and Family Medicine · 2026
13. Highlights from the 17th Japan Bioanalysis Forum SymposiumBioanalysis · 2026
14. Educational Artificial Intelligence Software to Support Assessment of Atopic Dermatitis SeverityThe Journal of Dermatology · 2026
15. Real-world profile and clinical impact of central nervous system adverse events in patients with ALK-positive NSCLC treated with first-line lorlatinib in Japan: The first interim analysis from the ROYAL studyInternational Journal of Lung Cancer · 2026
16. Pharmacological characteristics and clinical outcomes of Rimegepant (Nurtec® ODT), an oral CGRP receptor antagonist for the acute treatment and prevention of migraineFolia Pharmacologica Japonica · 2026
17. Quality of life with palbociclib plus tamoxifen in hormone receptor-positive, HER2-negative advanced breast cancer: results from PATHWAY, an Asian international, double-blind, randomized phase 3 trialBreast Cancer · 2026
18. The Burden of Transthyretin Amyloid Cardiomyopathy on Caregivers and Patients in Japan: A Cross‑Sectional Real‑World SurveyAdvances in Therapy · 2026
19. Characterization of Urinary Kidney Injury Biomarker Profiles in Healthy Japanese Subjects With Reference to a Counterpart US StudyClinical and Translational Science · 2026
20. Palbociclib plus tamoxifen ± goserelin in women with hormone receptor (HR)-positive, HER2-negative advanced breast cancer (BC): PATHWAY, an Asian international double-blind randomized phase 3 trial—Final overall survival (OS) analysis.Journal of Clinical Oncology · 2026